Study Highlight:

  • Intense IV insulin is not better than standard insulin shots at improving stroke recovery.  

Embargoed until 11:25 a.m. Hawaii Time/4:25 p.m. Eastern Time, Wednesday, Feb. 6, 2019

HONOLULU, Feb. 6, 2019 — Intravenous (IV) insulin did not improve stroke outcomes compared to standard blood sugar (glucose) control using insulin shots – answering a worldwide debate about the best way to control glucose in stroke patients. These primary late-breaking findings were presented at the American Stroke Association’s International Stroke Conference 2019, a world premier meeting for researchers and clinicians dedicated to the science and treatment of cerebrovascular disease.

Hyperglycemia, or increased glucose, is common in patients with acute ischemic stroke and is associated with poor recovery. There is a worldwide debate about the best way to control glucose levels in these patients.

The Stroke Hyperglycemia Insulin Network Effort (SHINE) study assessed the efficacy and safety of up to 72 hours of glucose control using continuous intravenous insulin infusion versus standard subcutaneous insulin injections in a multicenter, randomized, controlled trial of 1,151 patients enrolled at 63 sites across the United States.

Primary findings showed:

  • Intense glucose therapy via IV insulin, which lowers glucose to a target of 80-130 milligrams per deciliter (mg/dL), does not improve functional outcomes at 90 days compared to standard glucose control using insulin shots, which aims to lower glucose below 180 mg/dL.

  • In addition, intense glucose therapy increases the risk of very low blood glucose (hypoglycemia) and requires more resources such as increased supervision from nursing staff.

“This study provides clear evidence to guide the control of glucose levels in patients experiencing acute ischemic stroke and hyperglycemia, or increased glucose,” said Karen C. Johnston, M.D., M.Sc., professor of neurology and associate vice president for Clinical & Translational Research at the University of Virginia in Charlottesville.

Co-authors and disclosures are noted on the abstract.

The National Institute of Neurological Disorders and Stroke (NINDS) funded the study.

Note: Scientific presentation is 11:23 a.m. Hawaii Time/4:23 p.m. Eastern Time, Wednesday, Feb. 6, 2019.

Additional Resources:

Statements and conclusions of study authors that are presented at American Heart Association scientific meetings are solely those of the study authors and do not necessarily reflect association policy or position. The association makes no representation or warranty as to their accuracy or reliability. The association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific association programs and events. The association has strict policies to prevent these relationships from influencing the science content. Revenues from pharmaceutical and device corporations are available at


About the American Stroke Association

The American Stroke Association is devoted to saving people from stroke — the No. 2 cause of death in the world and a leading cause of serious disability. We team with millions of volunteers to fund innovative research, fight for stronger public health policies and provide lifesaving tools and information to prevent and treat stroke. The Dallas-based association officially launched in 1998 as a division of the American Heart Association. To learn more or to get involved, call 1-888-4STROKE or visit Follow us on Facebook and Twitter.

For Media Inquiries and ASA Expert Perspective: 214-706-1173

Bridgette McNeill: 214-706-1135;

For Public Inquiries: 1-800-AHA-USA1 (242-8721)

Feb. 6-8, 2019: AHA News Media Office at the

Honolulu Convention Center: 808-792-6530 and